

Jeffrey S Dome

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6720064/publications.pdf>

Version: 2024-02-01

148
papers

7,458
citations

36303

51
h-index

60623

81
g-index

159
all docs

159
docs citations

159
times ranked

6124
citing authors

#	ARTICLE	IF	CITATIONS
1	Recurrent Respiratory Papillomatosis With Complete Response to Systemic Bevacizumab Therapy. <i>Ear, Nose and Throat Journal</i> , 2024, 103, 100-101.	0.8	1
2	Renal tumors. , 2022, , 525-540.		0
3	ASO Video Abstract: Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosisâ€”A Report from the Childrenâ€™s Oncology Group Study AREN0534. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	1
4	Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosis: A Report from the Childrenâ€™s Oncology Group Study AREN0534. <i>Annals of Surgical Oncology</i> , 2022, 29, 3252-3261.	1.5	8
5	Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population. <i>Supportive Care in Cancer</i> , 2022, 30, 3513-3520.	2.2	4
6	Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT. <i>Blood Advances</i> , 2022, 6, 2520-2534.	5.2	19
7	White paper: Oncoâ€fertility in pediatric patients with Wilms tumor. <i>International Journal of Cancer</i> , 2022, , .	5.1	5
8	Authorsâ€™ Reply to the Letter to the Editor by Daniel M. Green. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, xlvii-xlviii.	4.9	0
9	Outcomes based on histopathologic response to preoperative chemotherapy in children with bilateral Wilms tumor: A prospective study (COG AREN0534). <i>Cancer</i> , 2022, 128, 2493-2503.	4.1	6
10	MP17-16â€fLONG-TERM OUTCOMES FOR PATIENTS WITH ANAPLASTIC BILATERAL WILMS TUMORS ENROLLED ON COG AREN0534. <i>Journal of Urology</i> , 2022, 207, .	0.4	0
11	Revisiting the Threshold for Cancer Genetics Referral in Patients With Wilms Tumor. <i>Journal of Clinical Oncology</i> , 2022, 40, 1853-1860.	1.6	5
12	Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533. <i>Journal of Clinical Oncology</i> , 2022, 40, 3047-3056.	1.6	19
13	Wilms Tumor. , 2021, , 139-162.		0
14	Estimated SARS-CoV-2 Seroprevalence in Healthy Children and Those with Chronic Illnesses in the Washington Metropolitan Area as of October 2020. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, e272-e274.	2.0	7
15	Targeting the HIF-1Î±-IGFBP2 axis therapeutically reduces IGF1-AKT signaling and blocks the growth and metastasis of relapsed anaplastic Wilms tumor. <i>Oncogene</i> , 2021, 40, 4809-4819.	5.9	12
16	Impact of the First Generation of Childrenâ€™s Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 978-985.	4.9	26
17	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29282.	1.5	3
18	New approaches to risk stratification for Wilms tumor. <i>Current Opinion in Pediatrics</i> , 2021, 33, 40-48.	2.0	36

#	ARTICLE	IF	CITATIONS
19	Outcome of Donor-Derived Tumor Associated Antigen-Specific T Cell Therapy in Patients with High-Risk or Relapsed Acute Leukemia Post Allogeneic BMT. <i>Blood</i> , 2021, 138, 2828-2828.	1.4	2
20	Pediatric Solid Tumors. , 2020, , 1703-1747.e11.		7
21	Summary of COVID-19 clinical practice adjustments across select institutions. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28411.	1.5	4
22	ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma—A Children's Oncology Group study. <i>Cancer</i> , 2020, 126, 5303-5310.	4.1	17
23	A prospective study of pediatric and adolescent renal cell carcinoma: A report from the Children's Oncology Group AREN0321 study. <i>Cancer</i> , 2020, 126, 5156-5164.	4.1	19
24	Results of Treatment for Patients With Multicentric or Bilaterally Predisposed Unilateral Wilms Tumor (AREN0534): A report from the Children's Oncology Group. <i>Cancer</i> , 2020, 126, 3516-3525.	4.1	45
25	Imaging Characteristics of Nephrogenic Rests Versus Small Wilms Tumors: A Report From the Children's Oncology Group Study AREN03B2. <i>American Journal of Roentgenology</i> , 2020, 214, 987-994.	2.2	28
26	Outcome analysis of stage I epithelial-predominant favorable-histology Wilms tumors: A report from Children's Oncology Group study AREN03B2. <i>Cancer</i> , 2020, 126, 2866-2871.	4.1	20
27	Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children's Oncology Group AREN0321 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1558-1568.	1.6	50
28	Reply to D.M. Green. <i>Journal of Clinical Oncology</i> , 2020, 38, 773-774.	1.6	1
29	BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a004820.	1.2	4
30	Reopening Schools Safely: The Case for Collaboration, Constructive Disruption of Pre-Coronavirus 2019 Expectations, and Creative Solutions. <i>Journal of Pediatrics</i> , 2020, 223, 183-185.	1.8	15
31	414...Enhancing T cell therapy for patients with relapsed/refractory Wilms tumor. , 2020, , .		0
32	Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2349-2359.	1.6	56
33	Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study. <i>European Journal of Cancer</i> , 2019, 118, 58-66.	2.8	32
34	Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report. <i>Journal of Clinical Oncology</i> , 2019, 37, 2769-2777.	1.6	44
35	Reply to L. Xie et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 1264-1265.	1.6	0
36	Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor. <i>Nature Communications</i> , 2019, 10, 5806.	12.8	27

#	ARTICLE	IF	CITATIONS
37	Outcome of Wilms tumor patients with bone metastasis enrolled on National Wilms Tumor Studies 1â€5: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27430.	1.5	12
38	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 1-6.	1.9	60
39	Wilms Tumor-Nephroblastoma. , 2019, , 11-29.		1
40	Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilmsâ€™ tumor. <i>JCI Insight</i> , 2019, 4, .	5.0	21
41	Reply to B. Zhang et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 1454-1455.	1.6	0
42	Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Childrenâ€™s Oncology Group AREN0533 Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1564-1570.	1.6	87
43	Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Childrenâ€™s Oncology Group. <i>Journal of Clinical Oncology</i> , 2018, 36, 3396-3403.	1.6	37
44	Reply to D.M. Green. <i>Journal of Clinical Oncology</i> , 2018, 36, 3179-3181.	1.6	1
45	A unique subset of low-risk Wilms tumors is characterized by loss of function of TRIM28 (KAP1), a gene critical in early renal development: A Childrenâ€™s Oncology Group study. <i>PLoS ONE</i> , 2018, 13, e0208936.	2.5	35
46	Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Childrenâ€™s Oncology Group Study AREN0532. <i>Journal of Clinical Oncology</i> , 2018, 36, 254-261.	1.6	78
47	The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing. <i>Cancer</i> , 2018, 124, 3381-3389.	4.1	72
48	A prospective study of pediatric renal cell carcinoma: A report from the Childrenâ€™s Oncology Group study AREN0321.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10516-10516.	1.6	4
49	Outcome of patients with intracranial relapse enrolled on national Wilms Tumor Study Group clinical trials. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26406.	1.5	6
50	Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor. <i>Annals of Surgery</i> , 2017, 265, 835-840.	4.2	77
51	A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. <i>Nature Genetics</i> , 2017, 49, 1487-1494.	21.4	255
52	Imaging of renal medullary carcinoma in children and young adults: a report from the Childrenâ€™s Oncology Group. <i>Pediatric Radiology</i> , 2017, 47, 1615-1621.	2.0	17
53	Comprehensive renal function evaluation in patients treated for synchronous bilateral Wilms tumor. <i>Journal of Pediatric Surgery</i> , 2017, 52, 98-103.	1.6	11
54	Surgical protocol violations in children with renal tumors provides an opportunity to improve pediatric cancer care: a report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1905-1910.	1.5	39

#	ARTICLE	IF	CITATIONS
55	Significance of <i>TP53</i> Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2016, 22, 5582-5591.	7.0	82
56	Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2016, 34, 3189-3194.	1.6	117
57	Pediatric cystic nephromas: distinctive features and frequent DICER1 mutations. <i>Human Pathology</i> , 2016, 48, 81-87.	2.0	33
58	Safety and feasibility of magnetic resonance-guided high intensity focused ultrasound (MR-HIFU) for the ablation of relapsed or refractory pediatric solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS10588-TPS10588.	1.6	0
59	Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2. <i>Cancer</i> , 2015, 121, 2457-2464.	4.1	92
60	Overall Survival and Renal Function of Patients With Synchronous Bilateral Wilms Tumor Undergoing Surgery at a Single Institution. <i>Annals of Surgery</i> , 2015, 262, 570-576.	4.2	52
61	Inflammatory myofibroblastic tumor as a second neoplasm after Wilms tumor. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1075-1077.	1.5	6
62	MLL1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours. <i>Nature Communications</i> , 2015, 6, 10013.	12.8	64
63	Recurrent DGCR8, DROSHA, and SIX Homeodomain Mutations in Favorable Histology Wilms Tumors. <i>Cancer Cell</i> , 2015, 27, 286-297.	16.8	244
64	Reply to Wilms tumor and breast cancer. <i>Cancer</i> , 2015, 121, 2100-2101.	4.1	0
65	The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma. <i>Cancer Biology and Therapy</i> , 2015, 16, 949-957.	3.4	24
66	Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. <i>Journal of Clinical Oncology</i> , 2015, 33, 2999-3007.	1.6	281
67	Comparison of diagnostic performance of CT and MRI for abdominal staging of pediatric renal tumors: a report from the Children's Oncology Group. <i>Pediatric Radiology</i> , 2015, 45, 166-172.	2.0	45
68	Outcome and prognostic factors in stage III favorable histology Wilms tumor (FHWT): A report from the Children's Oncology Group (COG) study AREN0532.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10010-10010.	1.6	2
69	Omission of lung radiation in patients with stage IV favorable histology Wilms Tumor (FHWT) showing complete lung nodule response after chemotherapy: A report from Children's Oncology Group study AREN0533.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10011-10011.	1.6	17
70	Clinical outcome and biological predictors of relapse following nephrectomy only for very low risk Wilms tumor (VLR WT): A report from Children's Oncology Group AREN0532.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10023-10023.	1.6	3
71	TP53 Mutational Status Is a Potential Marker for Risk Stratification in Wilms Tumour with Diffuse Anaplasia. <i>PLoS ONE</i> , 2014, 9, e109924.	2.5	82
72	Risk Stratification for Wilms Tumor: Current Approach and Future Directions. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 215-223.	3.8	124

#	ARTICLE	IF	CITATIONS
73	DICER1 mutations in childhood cystic nephroma and its relationship to DICER1-renal sarcoma. <i>Modern Pathology</i> , 2014, 27, 1267-1280.	5.5	153
74	Breast cancer in Wilms tumor survivors: New insights into primary and secondary prevention. <i>Cancer</i> , 2014, 120, 3598-3601.	4.1	2
75	Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor. <i>Cancer Genetics</i> , 2014, 207, 403-411.	0.4	13
76	Outcome of patients with stage II/favorable histology wilms tumor with and without local tumor spill: A report from the National Wilms Tumor Study Group. <i>Pediatric Blood and Cancer</i> , 2014, 61, 134-139.	1.5	39
77	Repeat nephron-sparing surgery for children with bilateral Wilms tumor. <i>Journal of Pediatric Surgery</i> , 2014, 49, 149-153.	1.6	30
78	Feasibility of using CT volume as a predictor of specimen weight in a subgroup of patients with low risk Wilms tumors registered on COG Study AREN03B2: Implications for central venous catheter placement. <i>Journal of Pediatric Urology</i> , 2014, 10, 969-973.	1.1	6
79	Aberrant activation, nuclear localization, and phosphorylation of yes-associated protein-1 in the embryonic kidney and Wilms tumor. <i>Pediatric Blood and Cancer</i> , 2014, 61, 198-205.	1.5	32
80	Real-time central review: A report of the first 3,000 patients enrolled on the Children's Oncology Group Renal Tumor Biology and Risk Stratification protocol AREN03B2.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10000-10000.	1.6	8
81	Treatment of stage IV favorable histology Wilms tumor with incomplete lung metastasis response after chemotherapy: A report from Children's Oncology Group study AREN0533.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10001-10001.	1.6	16
82	A phase 2 study of vincristine and irinotecan in metastatic diffuse anaplastic Wilms tumor: Results from the Children's Oncology Group AREN0321 study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10032-10032.	1.6	12
83	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10052-10052.	1.6	1
84	Primary nephrectomy and intraoperative tumor spill: Report from the Children's Oncology Group (COG) renal tumors committee. <i>Journal of Pediatric Surgery</i> , 2013, 48, 34-38.	1.6	62
85	Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: A report from the Children's Oncology Group. <i>Cancer</i> , 2013, 119, 3887-3894.	4.1	82
86	Children's Oncology Group's 2013 blueprint for research: Renal tumors. <i>Pediatric Blood and Cancer</i> , 2013, 60, 994-1000.	1.5	140
87	Margin status and tumor recurrence after nephron-sparing surgery for bilateral Wilms tumor. <i>Journal of Pediatric Surgery</i> , 2013, 48, 1481-1485.	1.6	30
88	Is adrenalectomy necessary during unilateral nephrectomy for Wilms Tumor? A report from the Children's Oncology Group. <i>Journal of Pediatric Surgery</i> , 2013, 48, 1598-1603.	1.6	26
89	Detection of Preoperative Wilms Tumor Rupture with CT: A Report from the Children's Oncology Group. <i>Radiology</i> , 2013, 266, 610-617.	7.3	51
90	Clinicopathologic Findings Predictive of Relapse in Children With Stage III Favorable-Histology Wilms Tumor. <i>Journal of Clinical Oncology</i> , 2013, 31, 1196-1201.	1.6	78

#	ARTICLE	IF	CITATIONS
91	Prognostic implications of gain of 1q in favorable histology Wilms tumor: A report from the Children's Oncology Group. Journal of Clinical Oncology, 2013, 31, 10014-10014.	1.6	0
92	A genome-wide association study identifies susceptibility loci for Wilms tumor. Nature Genetics, 2012, 44, 681-684.	21.4	72
93	Clinically Relevant Subsets Identified by Gene Expression Patterns Support a Revised Ontogenic Model of Wilms Tumor: A Children's Oncology Group Study. Neoplasia, 2012, 14, 742-IN21.	5.3	105
94	Lymph node involvement in Wilms tumor: results from National Wilms Tumor Studies 4 and 5. Journal of Pediatric Surgery, 2012, 47, 700-706.	1.6	83
95	Genomic Loss of Tumor Suppressor miRNA-204 Promotes Cancer Cell Migration and Invasion by Activating AKT/mTOR/Rac1 Signaling and Actin Reorganization. PLoS ONE, 2012, 7, e52397.	2.5	138
96	Evaluation of diagnostic performance of CT for detection of tumor thrombus in children with Wilms tumor: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2012, 58, 551-555.	1.5	65
97	Clinical significance of pulmonary nodules detected by CT and Not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies 4 and 5: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2012, 59, 631-635.	1.5	71
98	Strategy for management of retroperitoneal tumors with caval tumor thrombus. Journal of Pediatric Surgery, 2011, 46, 2065-2070.	1.6	23
99	Barriers to the Enrollment of Children in the Children's Oncology Group Study of Very Low Risk Wilms Tumor. Journal of Pediatric Hematology/Oncology, 2011, 33, 521-523.	0.6	8
100	Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in wilms tumor. Genes Chromosomes and Cancer, 2011, 50, 982-995.	2.8	54
101	WT1 Mutation and 11P15 Loss of Heterozygosity Predict Relapse in Very Low-Risk Wilms Tumors Treated With Surgery Alone: A Children's Oncology Group Study. Journal of Clinical Oncology, 2011, 29, 698-703.	1.6	75
102	Reply to B. Royer-Pokora et al. Journal of Clinical Oncology, 2011, 29, e487-e488.	1.6	0
103	Telomere Shortening Alters the Kinetics of the DNA Damage Response after Ionizing Radiation in Human Cells. Cancer Prevention Research, 2011, 4, 1973-1981.	1.5	37
104	Predicting Relapse in Favorable Histology Wilms Tumor Using Gene Expression Analysis: A Report from the Renal Tumor Committee of the Children's Oncology Group. Clinical Cancer Research, 2009, 15, 1770-1778.	7.0	59
105	Subsets of Very Low Risk Wilms Tumor Show Distinctive Gene Expression, Histologic, and Clinical Features. Clinical Cancer Research, 2009, 15, 6800-6809.	7.0	51
106	Loss of Heterozygosity at 2q37 in Sporadic Wilms' Tumor: Putative Role for miR-562. Clinical Cancer Research, 2009, 15, 5985-5992.	7.0	56
107	Anthropomorphic measurements and event-free survival in patients with favorable histology Wilms tumor: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2009, 52, 254-258.	1.5	10
108	Retroperitoneal lymph node dissection for pediatric renal cell carcinoma. Pediatric Blood and Cancer, 2009, 52, 430-430.	1.5	12

#	ARTICLE	IF	CITATIONS
109	Treatment of relapsed Wilms tumors: lessons learned. Expert Review of Anticancer Therapy, 2009, 9, 1807-1815.	2.4	77
110	Hepatic Metastasis at Diagnosis in Patients With Wilms Tumor is not an Independent Adverse Prognostic Factor for Stage IV Wilms Tumor. Annals of Surgery, 2009, 250, 642-648.	4.2	48
111	Wilms tumour: prognostic factors, staging, therapy and late effects. Pediatric Radiology, 2008, 38, 2-17.	2.0	140
112	The feasibility and outcome of nephron-sparing surgery for children with bilateral Wilms tumor. Cancer, 2008, 112, 2060-2070.	4.1	125
113	Treatment of recurrent clear cell sarcoma of the kidney with brain metastasis. Pediatric Blood and Cancer, 2008, 50, 246-249.	1.5	40
114	Current and Emerging Chemotherapy Treatment Strategies for Wilms Tumor in North America. Paediatric Drugs, 2008, 10, 115-124.	3.1	22
115	Molecular Characterization of the Pediatric Preclinical Testing Panel. Clinical Cancer Research, 2008, 14, 4572-4583.	7.0	116
116	ELR+-CXC Chemokines and Their Receptors in Early Metanephric Development. Journal of the American Society of Nephrology: JASN, 2007, 18, 2359-2370.	6.1	19
117	Topotecan Is Active Against Wilms' Tumor: Results of a Multi-Institutional Phase II Study. Journal of Clinical Oncology, 2007, 25, 3130-3136.	1.6	60
118	Telomere Biology of Pediatric Cancer. Cancer Investigation, 2007, 25, 197-208.	1.3	17
119	Delineation of a 1Mb breakpoint region at 1p13 in Wilms tumors by fine-tiling oligonucleotide array CGH. Genes Chromosomes and Cancer, 2007, 46, 607-615.	2.8	19
120	Significance of pleural effusion in neuroblastoma. Pediatric Blood and Cancer, 2007, 49, 906-908.	1.5	15
121	Treatment of Stage IV Malignant Rhabdoid Tumor of the Kidney (MRTK) With ICE and VDCy. Journal of Pediatric Hematology/Oncology, 2006, 28, 286-289.	0.6	26
122	Adjuvant therapy in pediatric patients with completely resected renal cell carcinoma. Pediatric Blood and Cancer, 2006, 46, 527-527.	1.5	7
123	Amplification and Overexpression of <i>CACNA1E</i> Correlates with Relapse in Favorable Histology Wilms' Tumors. Clinical Cancer Research, 2006, 12, 7284-7293.	7.0	52
124	Treatment of Anaplastic Histology Wilms' Tumor: Results From the Fifth National Wilms' Tumor Study. Journal of Clinical Oncology, 2006, 24, 2352-2358.	1.6	290
125	Cefixime Allows Greater Dose Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients With Refractory Solid Tumors. Journal of Clinical Oncology, 2006, 24, 563-570.	1.6	70
126	Blastemal Expression of Type I Insulin-Like Growth Factor Receptor in Wilms' Tumors Is Driven by Increased Copy Number and Correlates with Relapse. Cancer Research, 2006, 66, 11148-11155.	0.9	47

#	ARTICLE	IF	CITATIONS
127	Rhabdoid Tumor of the Kidney in The National Wilms' Tumor Study: Age at Diagnosis As a Prognostic Factor. <i>Journal of Clinical Oncology</i> , 2005, 23, 7641-7645.	1.6	227
128	Current Therapy for Wilms's™ Tumor. <i>Oncologist</i> , 2005, 10, 815-826.	3.7	179
129	High Telomerase RNA Expression Level Is an Adverse Prognostic Factor for Favorable-Histology Wilms' Tumor. <i>Journal of Clinical Oncology</i> , 2005, 23, 9138-9145.	1.6	61
130	Disappearance of the Telomere Dysfunction-Induced Stress Response in Fully Senescent Cells. <i>Cancer Research</i> , 2004, 64, 3748-3752.	0.9	71
131	Telomerase Expression Predicts Unfavorable Outcome in Osteosarcoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 3790-3797.	1.6	90
132	Significance of pleural effusion at diagnosis of Wilms tumor. <i>Pediatric Blood and Cancer</i> , 2004, 42, 145-148.	1.5	9
133	Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. <i>Cancer</i> , 2004, 101, 1575-1583.	4.1	152
134	Management of Wilms' tumour: current practice and future goals. <i>Lancet Oncology</i> , The, 2004, 5, 37-46.	10.7	167
135	Satellite DNA hypomethylation in karyotyped Wilms tumors. <i>Cancer Genetics and Cytogenetics</i> , 2003, 141, 97-105.	1.0	81
136	Clinical and biologic significance of nuclear unrest in Wilms tumor. <i>Cancer</i> , 2003, 97, 2318-2326.	4.1	30
137	Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. <i>British Journal of Haematology</i> , 2003, 120, 846-849.	2.5	118
138	Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. <i>Clinical Cancer Research</i> , 2003, 9, 5442-53.	7.0	135
139	Improved Survival for Patients With Recurrent Wilms Tumor: The Experience at St. Jude Children's Research Hospital. <i>Journal of Pediatric Hematology/Oncology</i> , 2002, 24, 192-198.	0.6	104
140	Treatment of Refractory Osteosarcoma With Fractionated Cyclophosphamide and Etoposide. <i>Journal of Pediatric Hematology/Oncology</i> , 2002, 24, 250-255.	0.6	35
141	Recent advances in Wilms tumor genetics. <i>Current Opinion in Pediatrics</i> , 2002, 14, 5-11.	2.0	135
142	Complete Response of Recurrent Cellular Congenital Mesoblastic Nephroma to Chemotherapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2002, 24, 478-481.	0.6	45
143	Treatment of Metastatic Rhabdoid Tumor of the Kidney. <i>Journal of Pediatric Hematology/Oncology</i> , 2002, 24, 385-388.	0.6	59
144	Hypomethylation and hypermethylation of DNA in Wilms tumors. <i>Oncogene</i> , 2002, 21, 6694-6702.	5.9	165

#	ARTICLE	IF	CITATIONS
145	Intraatrial and intracaval Wilms' tumor. <i>Journal of Pediatric Surgery</i> , 2001, 36, 1869-1871.	1.6	2
146	Telomerase Activity and Prognosis in Primary Breast Cancers. <i>Journal of Clinical Oncology</i> , 1999, 17, 3075-3081.	1.6	52
147	Three molecular determinants of malignant conversion and their potential as therapeutic targets. <i>Current Opinion in Oncology</i> , 1999, 11, 58.	2.4	5
148	Incorporation of fluorescently labeled actin and tropomyosin into muscle cells. <i>Cell Differentiation</i> , 1988, 23, 37-52.	0.4	35